PROGRAM

The 13th International HBV Cure Workshop 2026 will be held in Denver, Colorado on November 4, 2026, right before The Liver Meeting® (TLM) 2026 by AASLD. This highly anticipated workshop brings together global inter-disciplinary experts to provide a framework for how academia and industry should collaborate to achieve the goal of curing hepatitis B.

Since its inception in 2014, the International HBV Cure Workshop has been a pivotal scientific platform aimed at accelerating the progress towards finding a cure for HBV.

The HBV treatment landscape is experiencing significant transformations and is on the brink of a paradigm shift. The emergence of numerous new treatment options brings great hope for reducing the disease burden, simplifying treatment protocols, and potentially curing and eradicating HBV infection. To optimize curative treatments for HBV, distinguished speakers from around the world will present the latest therapeutic options.

Wednesday, November 4, 2026
7:30 AM - 8:00 AM
8:00 AM - 8:10 AM
Adam Gehring
8:00 AM - 9:40 AM

 

  • 08:10 – 08:30​ Baseline HBsAg levels in HBsAg loss, functional cure and setpoint after therapy discontinuation​
  • 08:30 – 08:50​ Partial cure and long-term outcomes: What data do we need?
  • 08:50 – 09:10 New virological and immunological biomarkers to improve our understanding on target engagement and functional cure prediction
  • 09:10 – 09:40​ Discussion​
Pietro Lampertico Maura Dandri Man-Fung Yuen Jordan Feld Fabien Zoulim
9:40 AM - 10:00 AM
10:00 AM - 11:30 AM

 

  • 10:00 – 10:20 HBV cure in special populations
  • 10:20 – 10:50​ Clinical perspective of  novel HBV combination therapies: Efficacy vs. AEs & Complexity?
  • 10:50 – 11:10​ How much are patients willing to accept to achieve durable functional cure?
  • 11:10 – 11:30 Discussion
Carla Coffin Raymond Schinazi Norah Terrault Mark Sulkowski Chari Cohen
11:30 AM - 12:30 PM
12:30 PM - 2:30 PM

 

  • 12:30 – 12:40 Brief Introduction of industry talks
  • 12:40 – 12:50 Evidence of vaccine efficacy in a heterogeneous patient population
  • 12:50 – 13:00 Durable HBsAg decline following a single injection of VRON-0200
  • 13:00 – 13:10 Opportunities for bepirovirsen re-treatment based on modeling of existing data
  • 13:10 – 13:20 Functional cure rates in treatment naive vs. treatment experienced patients receiving AHB-137
  • 13:20 – 13:30 Insights into sustained HBsAg reduction after discontinuation of Pevifoscovir
  • 13:30 – 13:40 Antiviral efficacy of epigenetic editor Tune-401
  • 13:40 – 13:50 Durable pgRNA loss in CHB patients treated with PBGENE-HBV supports path towards viral cure
  • 13:50 – 14:30 Discussion
Frida Abramov Sue Currie Ahmed Nader Audrey Lau Tse-I Lin Brian Cosgrove Emily Harrison Mark Sulkowski Man-Fung Yuen
2:30 PM - 3:00 PM
3:00 PM - 4:30 PM

 

  • 15:00 – 15:20​ Antisense oligonucleotides as the backbone for new combination therapies
  • 15:20 – 15:40​ How much would effective immunotherapy impact functional cure rates?
  • 15:40 – 16:20​ Discussion
Jordan Feld Harry Janssen Carla Coffin Adam Gehring Man-Fung Yuen Fabien Zoulim Chari Cohen
4:20 PM - 4:30 PM
Harry Janssen
5:00 PM - 6:30 PM
6:30 PM - 8:30 PM

*Subject to changes